{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:56:06Z","timestamp":1777438566865,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11886-019-1152-6","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T14:01:16Z","timestamp":1558188076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Aaron","family":"Shanker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Bhupathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,18]]},"reference":[{"issue":"4","key":"1152_CR1","first-page":"e38","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38\u2013360.","journal-title":"Circulation"},{"issue":"1","key":"1152_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.amjmed.2007.10.002","volume":"121","author":"JS Berger","year":"2008","unstructured":"Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43\u20139.","journal-title":"Am J Med"},{"issue":"7329","key":"1152_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Collaboration AT","year":"2002","unstructured":"Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"issue":"25","key":"1152_CR4","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","volume":"126","author":"Stephan D. Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, American College of Cardiology Foundation. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126(25):3097\u20133137.","journal-title":"Circulation"},{"issue":"4","key":"1152_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2165\/00129784-200707040-00006","volume":"7","author":"TJ Helton","year":"2007","unstructured":"Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007;7(4):289\u201397.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"1152_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archinte.163.10.1145","volume":"163","author":"H Jneid","year":"2003","unstructured":"Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med. 2003;163(10):1145\u201353.","journal-title":"Arch Intern Med"},{"issue":"7141","key":"1152_CR7","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","volume":"316","author":"C Baigent","year":"1998","unstructured":"Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (second international study of infarct survival) collaborative group. BMJ. 1998;316(7141):1337\u201343.","journal-title":"BMJ"},{"issue":"10","key":"1152_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJMoa0909475","volume":"363","author":"SR Mehta","year":"2010","unstructured":"Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"1152_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"9497","key":"1152_CR10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607\u201321.","journal-title":"Lancet"},{"issue":"24","key":"1152_CR11","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1161\/01.CIR.101.24.2823","volume":"101","author":"Y Cadroy","year":"2000","unstructured":"Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101(24):2823\u20138.","journal-title":"Circulation"},{"issue":"20","key":"1152_CR12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"14","key":"1152_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297\u2013309.","journal-title":"N Engl J Med"},{"issue":"11","key":"1152_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"9683","key":"1152_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"issue":"1","key":"1152_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"5","key":"1152_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"CM Gibson","year":"2011","unstructured":"Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815\u201321 e6.","journal-title":"Am Heart J"},{"issue":"10081","key":"1152_CR18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"\u2022 Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799\u2013808. A significant trial which established low-dose rivaroxaban did not result in higher bleeding rates in comparison to aspirin in recent ACS patients already taking a P2Y12 inhibitor.","journal-title":"Lancet"},{"issue":"14","key":"1152_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"John W. Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O\u2019Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, St\u00f6rk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S Rivaroxaban with or without aspirin in stable cardiovascular Disease. N Engl J Med 2017;377(14):1319\u20131330. A landmark trial which evaluated the roles of rivaroxaban with and without aspirin in comparison to aspirin monotherapy in the setting of secondary cardiovascular protection. The results demonstrated that rivaroxaban with aspirin was linked with fewer major adverse cardiovascular outcomes, but was associated with higher major bleeding events.","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"1152_CR20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MCA.0000000000000031","volume":"24","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628\u201335.","journal-title":"Coron Artery Dis"},{"issue":"9706","key":"1152_CR21","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R S\u00f8rensen","year":"2009","unstructured":"S\u00f8rensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, J\u00f8rgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967\u201374.","journal-title":"Lancet"},{"issue":"9","key":"1152_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","volume":"96","author":"SV Rao","year":"2005","unstructured":"Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200\u20136.","journal-title":"Am J Cardiol"},{"issue":"20","key":"1152_CR23","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","volume":"24","author":"M Moscucci","year":"2003","unstructured":"Moscucci M, Fox KA, Cannon CP, Klein W, L\u00f3pez-Send\u00f3n J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(20):1815\u201323.","journal-title":"Eur Heart J"},{"issue":"10","key":"1152_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077694","volume":"8","author":"P Sardar","year":"2013","unstructured":"Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One. 2013;8(10):e77694.","journal-title":"PLoS One"},{"issue":"4","key":"1152_CR25","doi-asserted-by":"publisher","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","volume":"41","author":"SS Anand","year":"2003","unstructured":"Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S\u20139S.","journal-title":"J Am Coll Cardiol"},{"key":"1152_CR26","unstructured":"FDA. Xarelto: Full prescribing information 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202439s025lbl.pdf"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1152-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T07:25:09Z","timestamp":1663485909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1152-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,18]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1152-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,18]]},"assertion":[{"value":"18 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Aaron Shanker and Vivek Bhupathi declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"56"}}